Law firm Stephenson Harwood LLP has advised Euronext Brussels-listed Acacia Pharma Group plc on its successful €25 million fundraising through the placing of 12.5 million new ordinary shares at €2 per share with institutional investors in Europe and the US. Admission of the placing shares to trading on Euronext Brussels became effective on 18 August.

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy.

Earlier this year, Acacia Pharma attained FDA approval in the US for its two lead product candidates – BARHEMSYS® and BYFAVO™ – both of which it is preparing to commercialise in the US. This fundraise will enable the company to implement its commercialisation strategy and the launch of these products in the US.

The Stephenson Harwood team was led by corporate partners Anthony Clare and David Dowding, with support from senior associate Alexa Whitehead and associate Jack Digby. Further assistance was provided by tax partner John Meehan and senior associate Hilary Barclay, commercial and technology partner Naomi Leach and associate Alison Llewellyn, and IP senior associate Jodie Lilir.

Jefferies International Limited and Guggenheim Securities, LLC acted as joint global coordinators and joint bookrunners, and Bank Degroof Petercam SA/NV acted as joint bookrunner and listing agent in connection with the fundraise.